Quick summary: Cutting prescription opioid supplies by more than 50% since their peak failed to stem the rise in drug overdose deaths in America, which are projected to reach nearly 70,000 in 2025 or about 70% higher than in 2012. The approach overlooked persistent demand fuelled by social and economic despair, prompting shifts to deadlier illicit fentanyl while abandoning many chronic pain patients and worsening mental health outcomes such as increased suicides. Healthcare practice and public policy must therefore address these root causes of vulnerability to enhance well-being and deliver meaningful reductions in harm.
For more than a decade, a central strategy in America’s response to the opioid crisis has been to cut the supply of prescription opioids. And in that narrow sense, the strategy succeeded: per capita prescribing rates have fallen by more than 50% since their peak. Yet for years afterward, overall drug overdose deaths continued to climb. And while a steep decline in 2024 offered hope, the crisis remains severe. Provisional data for 2025 project nearly 70,000 overall drug overdose deaths: a figure that stands at roughly 70% higher than in 2012, when opioid prescribing volumes were at their peak.
Why didn’t slashing prescriptions work? The answer is complex, but it reveals the deep limitations of a supply-only approach.
First, reducing supply does not reduce demand. Pain (whether emotional, physical, or social) does not disappear when access to drugs is restricted. In some cases, it may worsen when people are unable to obtain relief.
Consider the real-life testimonies from a 2020 public health study tracking pathways to illicit drug use in rural New England. Researchers found that sudden clinician-led prescription cut-offs frequently drove people to illicit markets. When Jessica’s clinician stopped her pills, she suffered severe, unexpected withdrawal and soon discovered street options were cheaper. Others, like Josh, felt forced to turn to heroin to manage chronic pain and keep working. “I need something for the pain so I can support myself and my family,” Josh explained, describing the impossible choice he faced after losing his medical care without a safety net. “I really don’t want to be on heroin, but I can’t get the prescription pills back because they don’t see me as a case that actually needs them.”
This desperate shift from the clinic to the street illustrates the Iron Law of Prohibition in action: the more tightly a substance is restricted while demand remains high, the more dangerous and potent the market’s replacement becomes. Populations caught in this wider cycle (whether they were managing chronic pain or misusing prescription opioids) moved to heroin, and then to far deadlier illicit fentanyl. The crisis did not shrink; it mutated.
Second, the lethality of the new drug supply changed everything. Fentanyl and its analogues are extraordinarily potent. Because a lethal dose is smaller than a grain of salt, accidental overdose is far more likely than with traditional prescription opioids. A single miscalculation, counterfeit pill, or contaminated batch can kill. Supply-side victories against prescription pills did nothing to reduce the extreme danger of drugs from the street.
Third, and most importantly, the underlying demand for these drugs has continued to grow. The social determinants of health that drive despair (such as widening income inequality, persistent poverty, eroded economic opportunity, worsening mental health, untreated trauma, and declining social connection) have not improved for many Americans. In communities hollowed out by deindustrialisation, the loss of stable jobs and the erosion of social infrastructure make substance use a tragic but functional response to chronic stress, pain, and loss of purpose.
As long as these upstream conditions remain unaddressed, demand for chemical relief will persist, regardless of which molecule is cheapest or most available.
Again, overdose deaths did not fall with fewer prescriptions but surged with the arrival of illicit fentanyl. In fact, despite a 50% reduction in medical opioid prescribing, the annual number of prescription opioid-related deaths has remained essentially unchanged for the past decade, hovering consistently between 13,000 and 17,000 fatalities. Crucially, the turnaround in 2024 appears more closely linked to disruptions in the illicit drug supply than to reductions in medical prescribing.
This indicates that supply-side efforts can be worthwhile. Targeted action against illicit fentanyl trafficking has value. But treating the opioid crisis primarily as a prescribing problem was always a mistake. It distracted us from the deeper drivers of demand and produced serious unintended consequences.
Chief among these was the damage inflicted on patients with chronic pain when a wave of panic led to their widespread abandonment. Misrepresenting these patients’ real medical need as a supply-side threat, the system restricted their access to care. As a result, many lost physical function, some were driven to the dangerous illicit market out of desperation, and others tragically died by suicide.
To solve this crisis, we must address the environmental conditions that create vulnerability. Real progress requires a paradigm shift in thinking and action that directly confronts the social, economic, and healthcare issues at the root of despair.
Success is not merely the absence of drugs. It is the presence of opportunity, dignity, connection, and hope.
We must confront the demand side with the same seriousness we have applied to supply, or we will keep fighting the same battle with different molecules.
Lynn R. Webster, MD, is a leading authority on pain and addiction medicine and a past president of the American Academy of Pain Medicine. He wrote The Painful Truth and its new follow-up with Sarah Eichberg, “Deconstructing Toxic Narratives: Data, Disparities, and a New Path Forward in the Opioid Crisis“.
